Norihiko “Nori” Oharu, located in Connecticut, is the Head of the Programming Center of Excellence (CoE) at Takeda Pharmaceutical Company Limited. In his capacity, Nori oversees teams responsible for managing Standards Programming and Automation, Ecosystem Management, Submission Standards and Governance, Reporting Metadata Governance, Safety Analytics, Specialized Data programming (PK/PD), data anonymization, and Real-World Data programming. After obtaining his master's degree in quantitative science, Nori started his career as a programmer in a CRO organization, handling programming tasks for pharmaceutical companies. He subsequently joined Pfizer, where he worked in the Oncology therapeutic area, overseeing breast cancer trials for regulatory submissions. Nori has a strong interest in innovative data analyses aimed at efficiently delivering medicine to patients and maintaining submission excellence. With his background in statistical and quantitative sciences, he is proficient in statistical programming and data analysis. Nori has led significant projects and initiatives within the organization and is highly regarded for his collaborative and effective leadership.
Starting a career in statistical programming within the pharmaceutical industry involves gaining technical proficiency, industry knowledge, and leadership abilities. Initially, as a junior programmer using SAS to analyze clinical trial data, you will begin to develop expertise in industry standards. Over time, advancing to lead teams, you will oversee programming deliverables for data reporting to support regulatory submissions, ultimately achieving a leadership position. In addition to technical skills, effective communication, and analytical thinking, strength in project management is critical in navigating the complex landscape of pharmaceutical research. Leading global projects and collaborating with cross-functional teams allowed me to gain insights into regulatory interactions and the drug development process from IND to drug approval. In discussion I will focus on my journey to be a leader in data science.
Dr. Jacob Gagnon is an associate director of biostatistics at Biogen and leads a team of medical researchers in the areas of neurology and immunology. He leads statistical methodology development efforts for the latest omics technologies (ie spatial transcriptomics, scRNAseq, single cell proteomics, etc), performs preclinical research, is a core member of the text mining center of excellence, and leads a ML/DL focus group. His team’s research interests include deep learning, machine learning, translational biology, omics analysis, and text mining. He obtained a PhD in statistics from UMASS Amherst and did postdoctoral work in biostatistics at WPI. After his postdoctoral work, he did biostatistics research for Abbvie, Roche, and then Biogen. He has authored/co-authored around 20 publications including three in Nature journals. Additionally, he has won multiple awards including: a winner of the PHUSE/FDA innovation challenge, NEDSI’s best application of theory award, and Wiley’s highly viewed article award.
Deep learning has been quite popular in recent years with many applications in the pharmaceutical space. Some applications include large language models applied to R&D, computer vision of medical images, digital twins, and text to image generation. In this talk, we will focus on deep learning best practices specifically in the area of MLops and LLMops. MLops, or machine learning operations, is a set of recommendations for the end-to-end life cycle of machine learning projects to aid in ML pipeline reproducibility, reliability, and automation. MLops includes model development and deployment as well as monitoring and retraining of models. We will conclude the talk with a discussion of LLMops, which includes particular guidance for the lifecycle of LLM projects.
Shailendra Phadke is the Global Head of Statistical Programming at Servier Pharmaceuticals. With extensive experience in various pharmaceutical companies and CROs, Shailendra has successfully led multiple global submissions. His current focus is on nurturing new leadership opportunities within his team and guiding the statistical programming team to innovate and integrate new technologies and programming languages into their activities.
Data analysis and data visualization are crucial components in the drug development process. During the conduct of clinical trial hey play a pivotal role, particularly in data monitoring and enhancing our ability to make quick, informed decisions. With the advent of AI and machine learning, we are witnessing rapid changes in the statistical programming domain within clinical development.
In my presentation, I will delve into these changes in detail. I will discuss how the role of statistical programmers is evolving and how AI tools are being integrated into data analysis and visualization processes. This integration is not only enhancing our efficiency but also improving the accuracy and depth of our data insights. I will share this exciting development and talk about how we can leverage these advancements to further the role of statistical programming in clinical development.
Madison Forrest is located in Connecticut and is a Manager of Programming in the Programming Center of Excellence at Takeda Pharmaceutical Company Limited. Madison works on programming and documentation related to regulatory submissions. Madison obtained an undergraduate degree in Statistics from UConn, and is currently pursuing her master’s degree in Data Analytics from Penn State. After graduating from UConn, she completed a statistical programming internship at Pfizer. From there, she was hired as an associate statistical programmer in the Oncology therapeutic area, working on breast cancer trials for regulatory submissions. Currently, she works on multiple projects related to regulatory submission, including programming of datasets, creating and reviewing regulatory documents, and providing expertise on a variety of submissions subjects.
This presentation chronicles my journey, from being one of only two undergraduates accepted into a Pfizer internship typically reserved for graduate students, to becoming a manager early in my career, and the factors that contributed to my success. We will discuss the importance of making connections, being well rounded and adaptable, and facing imposter syndrome.
Embracing discomfort, fostering strong relationships, and shifting perceptions of self-worth are key to succeeding in the pharmaceutical field. This talk challenges others to redefine qualifications, embrace growth, and confidently seize opportunities, regardless of perceived limits.